Based on a highly innovative therapeutic concept Profem develops specifically medicines for gynecological diseases with a hitherto unmet medical need.
Based on highly innovative scientific concepts ProFem develops new medicines for gynaecological diseases addressing a hitherto unmet medical need and therefore high market potential. The objective of the lead project Candiplus is the clinical development of a new medicine for the treatment of recurrent vulvovaginal Candidiasis. 5% of all women worldwide suffer significantly from this disease, which up to now cannot successfully be treated. The clinical “proof of principle” has already been obtained in first case studies. The start of the regular clinical study program is scheduled for the 4th quarter of 2012. IP rights comprise indication and formulation of the new medicine. Follow-up projects address further therapeutic areas with high medical need, such as the treatment of chronic infections of the bladder and overactive bladder syndrome.
+43 676 7203070